tert-Butyl 4-(5-bromo-3-nitropyridin-2-yl)piperazine-1-carboxylate

Catalog No. :
ACUYSQ782
CAS No. :
1221792-73-9
Molecular Formula :
C14H19BrN4O4
Molecular Weight :
387.23

IUPAC Name:tert-butyl 4-(5-bromo-3-nitropyridin-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(5-bromo-3-nitropyridin-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$6276.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(5-bromo-3-nitropyridin-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(5-bromo-3-nitropyridin-2-yl)piperazine-1-carboxylate
Molecular FormulaC14H19BrN4O4
Molecular Weight387.23
SMILESO=C(N1CCN(C2=NC=C(Br)C=C2[N+]([O-])=O)CC1)OC(C)(C)C
InChI KeyJKMCDPYFBNSYTM-UHFFFAOYSA-N
Synonymtert-Butyl 4-(5-bromo-3-nitro-2-pyridinyl)-tetrahydro-1(2H)-pyrazinecarboxylate;TERT-BUTYL 4-(5-BROMO-3-NITROPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLATE;1-Piperazinecarboxylic acid, 4-(5-bromo-3-nitro-2-pyridinyl)-, 1,1-dimethylethyl ester
CAS No.1221792-73-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H317-H319
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACUYSQ782 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACPXGV983 route compound structure diagram
    ACPXGV98367443-38-3 In Stock
  4. Then
  5. ACUYSQ782 route product structure diagram
    ACUYSQ7821221792-73-9
Inquiry

2. ACUYSQ782 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOPAN051 route compound structure diagram
    ACOPAN0511203499-08-4 In Stock
  4. Then
  5. ACUYSQ782 route product structure diagram
    ACUYSQ7821221792-73-9
Inquiry

Comments (0)